Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma, basal cell carcinoma and pancreatic adenocarcinoma) or hematological malignancy (except CML, ALL and AML).
Patient has pre-identified tumor with a PTCH1 or SMO mutation.
Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
You may not be if
Patients has received prior treatment with LDE225.
Patients has neuromuscular disorders associated with elevated CK (i.e. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis
Patients has primary CNS tumor or CNS tumor involvement
Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug
Clareo Health | LDE225 for Patients With PTCH1 or SMO Mutated Tumors
